NZ528402A - New process for the industrial synthesis of strontium ranelate and its hydrates - Google Patents
New process for the industrial synthesis of strontium ranelate and its hydratesInfo
- Publication number
- NZ528402A NZ528402A NZ528402A NZ52840203A NZ528402A NZ 528402 A NZ528402 A NZ 528402A NZ 528402 A NZ528402 A NZ 528402A NZ 52840203 A NZ52840203 A NZ 52840203A NZ 528402 A NZ528402 A NZ 528402A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- compound
- process according
- iii
- synthesis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 37
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 36
- 229940079488 strontium ranelate Drugs 0.000 title claims abstract description 25
- ZHEZAQJNZMLYBA-UHFFFAOYSA-J distrontium;5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate;octahydrate Chemical compound O.O.O.O.O.O.O.O.[Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N ZHEZAQJNZMLYBA-UHFFFAOYSA-J 0.000 title claims description 25
- 150000004677 hydrates Chemical class 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 77
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 238000010992 reflux Methods 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000011541 reaction mixture Substances 0.000 claims description 16
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 9
- UUCCCPNEFXQJEL-UHFFFAOYSA-L strontium dihydroxide Chemical compound [OH-].[OH-].[Sr+2] UUCCCPNEFXQJEL-UHFFFAOYSA-L 0.000 claims description 9
- 229910001866 strontium hydroxide Inorganic materials 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000005864 Sulphur Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 239000006184 cosolvent Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 claims description 4
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- -1 distrontium salt octahydrate Chemical compound 0.000 claims description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- YPKDDRKVYUMYEP-UHFFFAOYSA-J distrontium thiophene-2-carboxylate octahydrate Chemical compound O.O.O.O.O.O.O.O.[Sr+2].[Sr+2].S1C(=CC=C1)C(=O)[O-].S1C(=CC=C1)C(=O)[O-].S1C(=CC=C1)C(=O)[O-].S1C(=CC=C1)C(=O)[O-] YPKDDRKVYUMYEP-UHFFFAOYSA-J 0.000 claims 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 abstract 1
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- AYCCQDIBOMUCEW-UHFFFAOYSA-N methyl 5-[bis(2-methoxy-2-oxoethyl)amino]-4-cyano-3-(2-methoxy-2-oxoethyl)thiophene-2-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C=1SC(C(=O)OC)=C(CC(=O)OC)C=1C#N AYCCQDIBOMUCEW-UHFFFAOYSA-N 0.000 description 3
- BLYLWUDQKYBGJD-UHFFFAOYSA-N methyl 5-amino-4-cyano-3-(2-methoxy-2-oxoethyl)thiophene-2-carboxylate Chemical compound COC(=O)CC1=C(C(=O)OC)SC(N)=C1C#N BLYLWUDQKYBGJD-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- RNJOKCPFLQMDEC-UHFFFAOYSA-N 4(R),8-dimethyl-trans-2-nonenoyl-CoA Chemical compound COC(=O)CC(=O)CC(=O)OC RNJOKCPFLQMDEC-UHFFFAOYSA-N 0.000 description 2
- KNPBNTMMZCNVIE-UHFFFAOYSA-N 5-amino-3-(carboxymethyl)-4-cyanothiophene-2-carboxylic acid Chemical compound NC=1SC(C(O)=O)=C(CC(O)=O)C=1C#N KNPBNTMMZCNVIE-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- ZSANYRMTSBBUCA-UHFFFAOYSA-N diethyl 3-oxopentanedioate Chemical compound CCOC(=O)CC(=O)CC(=O)OCC ZSANYRMTSBBUCA-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- QZGJWBFWUITOJD-UHFFFAOYSA-M dodecyl-bis(2-hydroxyethyl)-methylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(CCO)CCO QZGJWBFWUITOJD-UHFFFAOYSA-M 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- IXLRCPSVPMSMMM-UHFFFAOYSA-N methyl 3-(dicyanomethylidene)-5-hydroxy-5-methoxypent-4-enoate Chemical compound COC(=O)CC(=C(C#N)C#N)C=C(O)OC IXLRCPSVPMSMMM-UHFFFAOYSA-N 0.000 description 1
- OLAPPGSPBNVTRF-UHFFFAOYSA-N naphthalene-1,4,5,8-tetracarboxylic acid Chemical compound C1=CC(C(O)=O)=C2C(C(=O)O)=CC=C(C(O)=O)C2=C1C(O)=O OLAPPGSPBNVTRF-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- DJSXNILVACEBLP-UHFFFAOYSA-N ranelic acid Chemical compound OC(=O)CN(CC(O)=O)C=1SC(C(O)=O)=C(CC(O)=O)C=1C#N DJSXNILVACEBLP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Inorganic Insulating Materials (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0211763A FR2844795B1 (fr) | 2002-09-24 | 2002-09-24 | Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ528402A true NZ528402A (en) | 2004-07-30 |
Family
ID=29415189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ528402A NZ528402A (en) | 2002-09-24 | 2003-09-23 | New process for the industrial synthesis of strontium ranelate and its hydrates |
Country Status (37)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004098618A2 (en) * | 2003-05-07 | 2004-11-18 | Osteologix A/S | Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions |
| ES2275218T3 (es) * | 2003-05-07 | 2007-06-01 | Osteologix A/S | Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos. |
| PL1732575T3 (pl) | 2004-02-26 | 2011-05-31 | Osteologix As | Związki zawierające stron do stosowania w zapobieganiu lub leczeniu stanów nekrotycznych kości |
| JP4954867B2 (ja) * | 2004-05-06 | 2012-06-20 | オステオロジックス エイ／エス | 有機金属塩類を製造するための高収率で迅速な合成法 |
| CA2571449C (en) | 2004-06-25 | 2015-12-08 | John Nikolaj Hvarre Christensen | Compositions comprising strontium and vitamin d and uses thereof |
| FR2875807B1 (fr) * | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| CN100538672C (zh) * | 2005-04-18 | 2009-09-09 | 索尼株式会社 | 控制设备和方法 |
| CN100391955C (zh) * | 2005-04-30 | 2008-06-04 | 河北医科大学 | 一种雷尼酸锶中间体的合成方法 |
| CA2619720A1 (en) * | 2005-08-19 | 2007-02-22 | Glenmark Pharmaceuticals Limited | Process for the preparation of strontium ranelate |
| US20070292535A1 (en) * | 2006-06-19 | 2007-12-20 | Tabbiner Philip S | Strontium compositions and methods of treating arthritic and or osteoporitic conditions |
| US20070292529A1 (en) * | 2006-06-19 | 2007-12-20 | Tabbiner Philip S | Strontium compositions and methods of treating osteoporotic conditions |
| FR2921367B1 (fr) * | 2007-09-26 | 2009-10-30 | Servier Lab | Nouveau procede de synthese du ranelate de strontium et de ses hydrates |
| US20120123131A1 (en) * | 2008-08-22 | 2012-05-17 | Koilpillai Joseph Prabahar | Process for the preparation of strontium ranelate |
| HU228820B1 (en) | 2010-01-14 | 2013-05-28 | Richter Gedeon Nyrt | Process for the preparation of distrontium ranelate |
| WO2011110597A1 (de) | 2010-03-11 | 2011-09-15 | Azad Pharmaceutical Ingredients Ag | Verfahren zur herstellung von strontiumranelat |
| WO2011124992A1 (en) * | 2010-03-24 | 2011-10-13 | Actavis Group Ptc Ehf | Substantially pure strontium ranelate |
| US9301945B2 (en) | 2011-07-21 | 2016-04-05 | Emory University | Methods for treating inflammatory conditions and states, and cancers by antagonizing NF-κB activation |
| CN102321068B (zh) * | 2011-08-01 | 2013-01-23 | 山东铂源药业有限公司 | 一种雷奈酸锶的制备方法 |
| WO2013175270A1 (en) * | 2012-05-25 | 2013-11-28 | Fleming Laboratories Limited | Improved process for the preparation of strontium ranelate hydrates and new polymorphic form of monohydrate |
| ES2505716T3 (es) | 2013-01-21 | 2015-09-04 | Galenicum Health S.L. | Composiciones farmacéuticas que comprenden una sal de ácido |
| CN103319454B (zh) * | 2013-06-14 | 2014-06-18 | 广东众生药业股份有限公司 | 一种高纯度雷尼酸四乙酯及其中间体的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2651497B1 (fr) * | 1989-09-01 | 1991-10-25 | Adir | Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| FR2749759B1 (fr) * | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
| FR2844797B1 (fr) * | 2002-09-24 | 2004-10-22 | Servier Lab | Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates |
| FR2844796A1 (fr) * | 2002-09-24 | 2004-03-26 | Servier Lab | Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates |
-
2002
- 2002-09-24 FR FR0211763A patent/FR2844795B1/fr not_active Expired - Fee Related
-
2003
- 2003-09-17 MY MYPI20033542A patent/MY134921A/en unknown
- 2003-09-22 AP AP2005003256A patent/AP1910A/xx active
- 2003-09-22 ME MEP-2008-689A patent/ME00455B/me unknown
- 2003-09-22 WO PCT/FR2003/002777 patent/WO2004029036A1/fr not_active Ceased
- 2003-09-22 HR HRP20050359AA patent/HRP20050359B1/hr not_active IP Right Cessation
- 2003-09-22 AU AU2003282179A patent/AU2003282179A1/en not_active Abandoned
- 2003-09-22 AU AU2003248281A patent/AU2003248281B2/en not_active Ceased
- 2003-09-22 EP EP03292319.5A patent/EP1403266B1/fr not_active Expired - Lifetime
- 2003-09-22 UA UAA200503858A patent/UA79156C2/uk unknown
- 2003-09-22 GE GEAP20048761A patent/GEP20074215B/en unknown
- 2003-09-22 OA OA1200500083A patent/OA12934A/en unknown
- 2003-09-22 DK DK03292319.5T patent/DK1403266T3/da active
- 2003-09-22 RS RSP20050240 patent/RS53509B1/sr unknown
- 2003-09-22 RS YUP-2005/0240A patent/RS20050240A/sr unknown
- 2003-09-22 ES ES03292319.5T patent/ES2478620T3/es not_active Expired - Lifetime
- 2003-09-22 PT PT3292319T patent/PT1403266E/pt unknown
- 2003-09-22 JP JP2003330440A patent/JP4136867B2/ja not_active Expired - Fee Related
- 2003-09-22 SI SI200332352T patent/SI1403266T1/sl unknown
- 2003-09-23 EA EA200300925A patent/EA007489B1/ru not_active IP Right Cessation
- 2003-09-23 BR BR0304213-8A patent/BR0304213A/pt not_active Application Discontinuation
- 2003-09-23 NO NO20034235A patent/NO328638B1/no not_active IP Right Cessation
- 2003-09-23 NZ NZ528402A patent/NZ528402A/en not_active IP Right Cessation
- 2003-09-23 KR KR1020030065783A patent/KR100551501B1/ko not_active Expired - Fee Related
- 2003-09-23 MX MXPA03008643A patent/MXPA03008643A/es active IP Right Grant
- 2003-09-23 CA CA002442878A patent/CA2442878C/fr not_active Expired - Fee Related
- 2003-09-23 PL PL362365A patent/PL214400B1/pl unknown
- 2003-09-23 ZA ZA200307409A patent/ZA200307409B/xx unknown
- 2003-09-23 AR ARP030103453A patent/AR041355A1/es not_active Application Discontinuation
- 2003-09-24 MA MA27321A patent/MA26102A1/fr unknown
- 2003-09-24 US US10/669,301 patent/US7214805B2/en not_active Expired - Fee Related
- 2003-09-24 CN CNB031348130A patent/CN1212321C/zh not_active Expired - Fee Related
- 2003-09-24 SG SG200305555A patent/SG110071A1/en unknown
-
2005
- 2005-03-08 IL IL167316A patent/IL167316A/en not_active IP Right Cessation
- 2005-03-18 CR CR7764A patent/CR7764A/es unknown
- 2005-03-23 TN TNP2005000087A patent/TNSN05087A1/fr unknown
- 2005-04-19 IS IS7807A patent/IS7807A/is unknown
- 2005-04-22 EC EC2005005741A patent/ECSP055741A/es unknown
-
2014
- 2014-06-05 CY CY20141100397T patent/CY1115162T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ528402A (en) | New process for the industrial synthesis of strontium ranelate and its hydrates | |
| AU2003248280B2 (en) | New process for the industrial synthesis of tetraesters of 5-[bis(carboxymethyl)amino]-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates | |
| JP2009132676A (ja) | ストロンチウムラネレートおよびその水和物の新規な合成法 | |
| US20040059135A1 (en) | Process for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates | |
| WO2010021000A2 (en) | A process for the preparation of strontium ranelate | |
| CN112279805B (zh) | 制备1-（3-甲氧基吡啶-2-基）-2-丙酮的方法 | |
| CN1910180B (zh) | 制备2-(乙氧基甲基)-托烷衍生物的方法 | |
| CN113185470A (zh) | 一种丙硫菌唑的制备方法 | |
| CZ297555B6 (cs) | Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| S38A | Application for proceedings under section 38 (amendment of specification with leave of commissioner) |
Free format text: BY WAY OF CORRECTION |
|
| S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 SEP 2016 BY AJ PARK Effective date: 20130701 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 SEP 2017 BY AJ PARK Effective date: 20160725 |
|
| LAPS | Patent lapsed |